What's the most recent regulatory action in Controlled ovarian stimulation?

Most recent: Estring — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/controlled-ovarian-stimulation.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Controlled ovarian stimulation — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Controlled ovarian stimulation (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Controlled ovarian stimulation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Slynd	DROSPIRENONE	Exeltis Usa Inc	Progestin	Mineralocorticoid receptor	2019-01-01
Femara	letrozole	Novartis AG	Aromatase Inhibitor [EPC]	aromatase enzyme	1997-07-25
Glucophage	metformin	Generic (originally Merck Serono/Lipha)	Dipeptidyl Peptidase 4 Inhibitor [EPC]	5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2	1995-03-03
Estrace	ESTRADIOL	Pfizer	Estrogen	Estrogen receptor	1975-01-01
Jadelle	LEVONORGESTREL	Fdn Consumer	Progestin	Progesterone receptor	1968-01-01
Clomid	clomifene	Sanofi	Estrogen Agonist/Antagonist	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	1967-01-01
Micronor	norethisterone	Johnson & Johnson	Progestin	GnRH receptors	1962-01-01
Ortho-Novum 10/11-21	Ethinylestradiol	Merck & Co.	Estrogen	Estrogen receptor	1943-01-01
Choriogonadotropin	chorionic gonadotrophin	Ferring
Glucophage	Glucophage	Dr. Reddy's Laboratories Limited		5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-11 — Estring · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Dr. Reddy's Laboratories Limited · 1 drug in Controlled ovarian stimulation
Exeltis Usa Inc · 1 drug in Controlled ovarian stimulation
Fdn Consumer · 1 drug in Controlled ovarian stimulation
Ferring · 1 drug in Controlled ovarian stimulation
Generic (originally Merck Serono/Lipha) · 1 drug in Controlled ovarian stimulation
Johnson & Johnson · 1 drug in Controlled ovarian stimulation
M.D. Anderson Cancer Center · 1 drug in Controlled ovarian stimulation
Merck & Co. · 1 drug in Controlled ovarian stimulation
Novartis AG · 1 drug in Controlled ovarian stimulation
Pfizer · 1 drug in Controlled ovarian stimulation
Pfizer Inc. · 1 drug in Controlled ovarian stimulation
Sanofi · 1 drug in Controlled ovarian stimulation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Controlled ovarian stimulation:

Cite this brief

Drug Landscape (2026). Controlled ovarian stimulation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/controlled-ovarian-stimulation. Accessed 2026-06-10.

Controlled ovarian stimulation full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing